Literature DB >> 26456717

Examining Longitudinal Stimulant Use and Treatment Attendance as Parallel Outcomes in Two Contingency Management Randomized Clinical Trials.

Sterling McPherson1, Olivia Brooks2, Celestina Barbosa-Leiker2, Crystal Lederhos2, Amanda Lamp3, Sean Murphy4, Matthew Layton5, John Roll4.   

Abstract

The primary aim of this study was to examine stimulant use and longitudinal treatment attendance in one 'parallel outcomes' model in order to determine how these two outcomes are related to one another during treatment, and to quantify how the intervention impacts these two on- and off-target outcomes differently. Data came from two multi-site randomized clinical trials (RCTs) of contingency management (CM) that targeted stimulant use. We used parallel multilevel modeling to examine the impact of multiple pre-specified covariates, including selected Addiction Severity Index (ASI) scores, age and sex, in addition to CM on concurrent attendance and stimulant use in two separate analyses, i.e., one per trial. In one trial, CM was positively associated with attending treatment throughout the trial (β=0.060, p<0.05). In the second trial, CM predicted negative urinalysis ((-)UA) over the 12-week treatment period (β=0.069, p<0.05). In both trials, there was a significant, positive relationship between attendance and (-)UA submission, but in the first trial a (-)UA at both baseline and over time was related to attendance over time (r=0.117; r=0.013, respectively) and in the second trial, a (-)UA submission at baseline was associated with increased attendance over time (r=0.055). These findings indicate that stimulant use and treatment attendance over time are related but distinct outcomes that, when analyzed simultaneously, portray a more informative picture of their predictors and the separate trajectories of each. This 'indirect reinforcement' between two clinically meaningful on-target (directly reinforced behavior) and off-target (indirectly reinforced behavior) outcomes is in need of further examination in order to fully exploit the potential clinical benefits that could be realized in substance use disorder treatment trials.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical trials; Contingency management; Parallel growth modeling; Stimulant use; Treatment attendance

Mesh:

Substances:

Year:  2015        PMID: 26456717      PMCID: PMC4695378          DOI: 10.1016/j.jsat.2015.08.008

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  45 in total

Review 1.  A comprehensive guide to the application of contingency management procedures in clinical settings.

Authors:  N M Petry
Journal:  Drug Alcohol Depend       Date:  2000-02-01       Impact factor: 4.492

2.  Reinforcement of drug abstinence: a behavioral approach to drug abuse treatment.

Authors:  M L Stitzer; G E Bigelow; I Liebson
Journal:  NIDA Res Monogr       Date:  1979-06

3.  Selection of a substance use disorder diagnostic instrument by the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Robert F Forman; Dace Svikis; Ivan D Montoya; Jack Blaine
Journal:  J Subst Abuse Treat       Date:  2004-07

4.  Contingent payment procedures for smoking reduction and cessation.

Authors:  M L Stitzer; C S Rand; G E Bigelow; A M Mead
Journal:  J Appl Behav Anal       Date:  1986

5.  Give them prizes, and they will come: contingency management for treatment of alcohol dependence.

Authors:  N M Petry; B Martin; J L Cooney; H R Kranzler
Journal:  J Consult Clin Psychol       Date:  2000-04

6.  Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence.

Authors:  A J Budney; S T Higgins; K J Radonovich; P L Novy
Journal:  J Consult Clin Psychol       Date:  2000-12

7.  Voucher-based reinforcement of opiate abstinence during methadone detoxification.

Authors:  Elias Robles; Maxine L Stitzer; Eric C Strain; George E Bigelow; Kenneth Silverman
Journal:  Drug Alcohol Depend       Date:  2002-01-01       Impact factor: 4.492

8.  The use of the DSM-III-R Checklist for initial diagnostic assessments.

Authors:  J J Hudziak; J E Helzer; M W Wetzel; K B Kessel; B McGee; A Janca; T Przybeck
Journal:  Compr Psychiatry       Date:  1993 Nov-Dec       Impact factor: 3.735

9.  Contingent methadone delivery: effects on illicit-opiate use.

Authors:  S T Higgins; M L Stitzer; G E Bigelow; I A Liebson
Journal:  Drug Alcohol Depend       Date:  1986-07       Impact factor: 4.492

10.  Influence of an alternative reinforcer on human cocaine self-administration.

Authors:  S T Higgins; W K Bickel; J R Hughes
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

View more
  8 in total

1.  Decreases in smoking during treatment for methamphetamine-use disorders: preliminary evidence.

Authors:  Sterling McPherson; Michael Orr; Crystal Lederhos; Michael McDonell; Emily Leickly; Katherine Hirchak; Oladunni A Oluwoye; Sean M Murphy; Matthew Layton; John M Roll
Journal:  Behav Pharmacol       Date:  2018-06       Impact factor: 2.293

2.  Pilot investigation: randomized-controlled analog trial for alcohol and tobacco smoking co-addiction using contingency management.

Authors:  Michael F Orr; Crystal Lederhos Smith; Myles Finlay; Samantha C Martin; Olivia Brooks; Oladunni A Oluwoye; Emily Leickly; Michael McDonell; Ekaterina Burduli; Celestina Barbosa-Leiker; Matt Layton; John M Roll; Sterling M McPherson
Journal:  Behav Pharmacol       Date:  2018-08       Impact factor: 2.293

3.  Cardiorespiratory fitness and body composition of stimulant users: A baseline analysis of the STRIDE cohort.

Authors:  Mark Stoutenberg; Chad D Rethorst; Denise C Vidot; Tracy L Greer; Madhukar H Trivedi
Journal:  J Subst Abuse Treat       Date:  2017-05-10

4.  Volunteer Recovery Support for Adolescents: Using propensity score based methods to understand dosage effects within a randomized controlled trial.

Authors:  Mark D Godley; Lora L Passetti; Brooke D Hunter; Beth Ann Griffin
Journal:  J Subst Abuse Treat       Date:  2021-10-08

5.  Predictors of tobacco and alcohol co-use from ages 15 to 32: The Amsterdam Growth and Health Longitudinal Study.

Authors:  Sterling M McPherson; Ekaterina Burduli; Crystal Lederhos Smith; Olivia Brooks; Michael F Orr; Celestina Barbosa-Leiker; Trynke Hoekstra; Michael G McDonell; Sean M Murphy; Matthew Layton; John M Roll
Journal:  Exp Clin Psychopharmacol       Date:  2018-08-27       Impact factor: 3.157

6.  Contingency management for alcohol use disorder reduces cannabis use among American Indian and Alaska Native adults.

Authors:  Katherine A Hirchak; Abram J Lyons; Jalene L Herron; Gordon Kordas; Jennifer L Shaw; Kelley Jansen; Jaedon P Avey; Sterling M McPherson; Dennis Donovan; John Roll; Dedra Buchwald; Richard Ries; Michael G McDonell
Journal:  J Subst Abuse Treat       Date:  2021-12-11

Review 7.  A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies.

Authors:  Sterling M McPherson; Ekaterina Burduli; Crystal Lederhos Smith; Jalene Herron; Oladunni Oluwoye; Katherine Hirchak; Michael F Orr; Michael G McDonell; John M Roll
Journal:  Subst Abuse Rehabil       Date:  2018-08-13

Review 8.  What are the ethical implications of using prize-based contingency management in substance use? A scoping review.

Authors:  Marilou Gagnon; Alayna Payne; Adrian Guta
Journal:  Harm Reduct J       Date:  2021-08-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.